Immunological and clinical factors associated with adverse systemic reactions during the build-up phase of honeybee venom immunotherapy
Summary Background Adverse systemic reactions (SRs) are more common in honeybee venom immunotherapy (VIT) than in wasp VIT. Factors that might be associated with SRs during the honeybee VIT are poorly understood. Objective Our aim was to evaluate risk factors for SRs during the build‐up phase of hon...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental allergy 2015-10, Vol.45 (10), p.1579-1589 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1589 |
|---|---|
| container_issue | 10 |
| container_start_page | 1579 |
| container_title | Clinical and experimental allergy |
| container_volume | 45 |
| creator | Korošec, P. Žiberna, K. Šilar, M. Dežman, M. Čelesnik Smodiš, N. Rijavec, M. Kopač, P. Eržen, R. Lalek, N. Bajrović, N. Košnik, M. Zidarn, M. |
| description | Summary
Background
Adverse systemic reactions (SRs) are more common in honeybee venom immunotherapy (VIT) than in wasp VIT. Factors that might be associated with SRs during the honeybee VIT are poorly understood.
Objective
Our aim was to evaluate risk factors for SRs during the build‐up phase of honeybee venom immunotherapy.
Methods
We included 93 patients who underwent ultra‐rush honeybee VIT. The adverse SRs and their severity was compared to various immunological (sIgE, tIgE, basophil CD63 response, baseline tryptase, and skin tests), patient‐specific (age, sex, cardiovascular conditions and medications, and other allergic diseases), and sting‐specific factors (anaphylaxis severity, time interval to onset of symptoms, and absence of cutaneous symptoms).
Results
Twenty‐three patients (24.7%) experienced mild SRs and 13 patients (14%) severe SRs. In five patients with severe SRs, the build‐up was stopped. High basophil allergen sensitivity, evaluated as dose–response curve metrics of EC15, EC50, CD‐sens, AUC, or the response to submaximal 0.01 μg/mL of venom concentration, was the most significant risk factor and only independent predictor of severe SRs and/or build‐up stop. Time interval of |
| doi_str_mv | 10.1111/cea.12582 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1713528117</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1713528117</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3912-4634edd867a681541b9123b760691c8ca208af26af8a8eb241882300bfa703cd3</originalsourceid><addsrcrecordid>eNp10ctu1DAUBmALgei0sOAFkCU2sEjrS-I4y2pUppXKZQHq0jpxTjouSRzspCVP0NfGnWm7QMIby9Z3flv6CXnH2TFP68QiHHNRaPGCrLhURSbSeklWrCryrNRVfkAOY7xhjMmi0q_JgVAsV5qVK3J_0ffz4Dt_7Sx0FIaG2s4Nu0MLdvIhUojRWwcTNvTOTVsKzS2GiDQuccLeWRowSeeHSJs5uOGaTluk9ey6JptHOm4hYd_SrR9wqRHpLQ6-p273cqIBxuUNedVCF_Ht435Efn4--7E-zy6_bS7Wp5eZlRUXWa5kjk2jVQlK8yLndbqVdamYqrjVFgTT0AoFrQaNtci51kIyVrdQMmkbeUQ-7nPH4H_PGCfTu2ix62BAP0fDSy4LoTkvE_3wD73xcxjS7x6UkJXMK57Up72ywccYsDVjcD2ExXBmHtoxqR2zayfZ94-Jc91j8yyf6kjgZA_uXIfL_5PM-uz0KTLbT7jUxZ_nCQi_jCplWZirrxtzXlxtqi_5d1PIv1_CqV4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1712393491</pqid></control><display><type>article</type><title>Immunological and clinical factors associated with adverse systemic reactions during the build-up phase of honeybee venom immunotherapy</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Korošec, P. ; Žiberna, K. ; Šilar, M. ; Dežman, M. ; Čelesnik Smodiš, N. ; Rijavec, M. ; Kopač, P. ; Eržen, R. ; Lalek, N. ; Bajrović, N. ; Košnik, M. ; Zidarn, M.</creator><creatorcontrib>Korošec, P. ; Žiberna, K. ; Šilar, M. ; Dežman, M. ; Čelesnik Smodiš, N. ; Rijavec, M. ; Kopač, P. ; Eržen, R. ; Lalek, N. ; Bajrović, N. ; Košnik, M. ; Zidarn, M.</creatorcontrib><description>Summary
Background
Adverse systemic reactions (SRs) are more common in honeybee venom immunotherapy (VIT) than in wasp VIT. Factors that might be associated with SRs during the honeybee VIT are poorly understood.
Objective
Our aim was to evaluate risk factors for SRs during the build‐up phase of honeybee venom immunotherapy.
Methods
We included 93 patients who underwent ultra‐rush honeybee VIT. The adverse SRs and their severity was compared to various immunological (sIgE, tIgE, basophil CD63 response, baseline tryptase, and skin tests), patient‐specific (age, sex, cardiovascular conditions and medications, and other allergic diseases), and sting‐specific factors (anaphylaxis severity, time interval to onset of symptoms, and absence of cutaneous symptoms).
Results
Twenty‐three patients (24.7%) experienced mild SRs and 13 patients (14%) severe SRs. In five patients with severe SRs, the build‐up was stopped. High basophil allergen sensitivity, evaluated as dose–response curve metrics of EC15, EC50, CD‐sens, AUC, or the response to submaximal 0.01 μg/mL of venom concentration, was the most significant risk factor and only independent predictor of severe SRs and/or build‐up stop. Time interval of <5 min after sting to onset of symptoms and lower specific IgEs to rApi m1 was also associated with severe SRs. There was no difference in other immunological, patient‐specific, or sting‐specific factors, including the baseline tryptase. None of the studied factors was associated with mild SRs.
Conclusion and Clinical Relevance
High basophil allergen CD63 sensitivity phenotype was a major indicator of severe adverse SRs during the build‐up phase of honeybee VIT. Possibly role was also showed for short latency to filed sting reaction and low sIgE to rApi m1. Before honeybee VIT, measurement of basophil allergen sensitivity should be used to identify patients with a high risk for severe side‐effects.</description><identifier>ISSN: 0954-7894</identifier><identifier>EISSN: 1365-2222</identifier><identifier>DOI: 10.1111/cea.12582</identifier><identifier>PMID: 26046807</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; adverse systemic reactions ; Aged ; basophils ; Basophils - immunology ; Basophils - metabolism ; Bee Venoms - administration & dosage ; Bee Venoms - adverse effects ; CD63 ; Dose-Response Relationship, Drug ; Female ; honeybee venom allergy ; Humans ; Hypersensitivity - blood ; Hypersensitivity - immunology ; IgE ; immunotherapy ; Immunotherapy - adverse effects ; Male ; Middle Aged ; risk factors ; Tetraspanin 30 - blood ; Tetraspanin 30 - immunology</subject><ispartof>Clinical and experimental allergy, 2015-10, Vol.45 (10), p.1579-1589</ispartof><rights>2015 John Wiley & Sons Ltd</rights><rights>2015 John Wiley & Sons Ltd.</rights><rights>Copyright © 2015 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3912-4634edd867a681541b9123b760691c8ca208af26af8a8eb241882300bfa703cd3</citedby><cites>FETCH-LOGICAL-c3912-4634edd867a681541b9123b760691c8ca208af26af8a8eb241882300bfa703cd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fcea.12582$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fcea.12582$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26046807$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Korošec, P.</creatorcontrib><creatorcontrib>Žiberna, K.</creatorcontrib><creatorcontrib>Šilar, M.</creatorcontrib><creatorcontrib>Dežman, M.</creatorcontrib><creatorcontrib>Čelesnik Smodiš, N.</creatorcontrib><creatorcontrib>Rijavec, M.</creatorcontrib><creatorcontrib>Kopač, P.</creatorcontrib><creatorcontrib>Eržen, R.</creatorcontrib><creatorcontrib>Lalek, N.</creatorcontrib><creatorcontrib>Bajrović, N.</creatorcontrib><creatorcontrib>Košnik, M.</creatorcontrib><creatorcontrib>Zidarn, M.</creatorcontrib><title>Immunological and clinical factors associated with adverse systemic reactions during the build-up phase of honeybee venom immunotherapy</title><title>Clinical and experimental allergy</title><addtitle>Clin Exp Allergy</addtitle><description>Summary
Background
Adverse systemic reactions (SRs) are more common in honeybee venom immunotherapy (VIT) than in wasp VIT. Factors that might be associated with SRs during the honeybee VIT are poorly understood.
Objective
Our aim was to evaluate risk factors for SRs during the build‐up phase of honeybee venom immunotherapy.
Methods
We included 93 patients who underwent ultra‐rush honeybee VIT. The adverse SRs and their severity was compared to various immunological (sIgE, tIgE, basophil CD63 response, baseline tryptase, and skin tests), patient‐specific (age, sex, cardiovascular conditions and medications, and other allergic diseases), and sting‐specific factors (anaphylaxis severity, time interval to onset of symptoms, and absence of cutaneous symptoms).
Results
Twenty‐three patients (24.7%) experienced mild SRs and 13 patients (14%) severe SRs. In five patients with severe SRs, the build‐up was stopped. High basophil allergen sensitivity, evaluated as dose–response curve metrics of EC15, EC50, CD‐sens, AUC, or the response to submaximal 0.01 μg/mL of venom concentration, was the most significant risk factor and only independent predictor of severe SRs and/or build‐up stop. Time interval of <5 min after sting to onset of symptoms and lower specific IgEs to rApi m1 was also associated with severe SRs. There was no difference in other immunological, patient‐specific, or sting‐specific factors, including the baseline tryptase. None of the studied factors was associated with mild SRs.
Conclusion and Clinical Relevance
High basophil allergen CD63 sensitivity phenotype was a major indicator of severe adverse SRs during the build‐up phase of honeybee VIT. Possibly role was also showed for short latency to filed sting reaction and low sIgE to rApi m1. Before honeybee VIT, measurement of basophil allergen sensitivity should be used to identify patients with a high risk for severe side‐effects.</description><subject>Adolescent</subject><subject>Adult</subject><subject>adverse systemic reactions</subject><subject>Aged</subject><subject>basophils</subject><subject>Basophils - immunology</subject><subject>Basophils - metabolism</subject><subject>Bee Venoms - administration & dosage</subject><subject>Bee Venoms - adverse effects</subject><subject>CD63</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>honeybee venom allergy</subject><subject>Humans</subject><subject>Hypersensitivity - blood</subject><subject>Hypersensitivity - immunology</subject><subject>IgE</subject><subject>immunotherapy</subject><subject>Immunotherapy - adverse effects</subject><subject>Male</subject><subject>Middle Aged</subject><subject>risk factors</subject><subject>Tetraspanin 30 - blood</subject><subject>Tetraspanin 30 - immunology</subject><issn>0954-7894</issn><issn>1365-2222</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10ctu1DAUBmALgei0sOAFkCU2sEjrS-I4y2pUppXKZQHq0jpxTjouSRzspCVP0NfGnWm7QMIby9Z3flv6CXnH2TFP68QiHHNRaPGCrLhURSbSeklWrCryrNRVfkAOY7xhjMmi0q_JgVAsV5qVK3J_0ffz4Dt_7Sx0FIaG2s4Nu0MLdvIhUojRWwcTNvTOTVsKzS2GiDQuccLeWRowSeeHSJs5uOGaTluk9ey6JptHOm4hYd_SrR9wqRHpLQ6-p273cqIBxuUNedVCF_Ht435Efn4--7E-zy6_bS7Wp5eZlRUXWa5kjk2jVQlK8yLndbqVdamYqrjVFgTT0AoFrQaNtci51kIyVrdQMmkbeUQ-7nPH4H_PGCfTu2ix62BAP0fDSy4LoTkvE_3wD73xcxjS7x6UkJXMK57Up72ywccYsDVjcD2ExXBmHtoxqR2zayfZ94-Jc91j8yyf6kjgZA_uXIfL_5PM-uz0KTLbT7jUxZ_nCQi_jCplWZirrxtzXlxtqi_5d1PIv1_CqV4</recordid><startdate>201510</startdate><enddate>201510</enddate><creator>Korošec, P.</creator><creator>Žiberna, K.</creator><creator>Šilar, M.</creator><creator>Dežman, M.</creator><creator>Čelesnik Smodiš, N.</creator><creator>Rijavec, M.</creator><creator>Kopač, P.</creator><creator>Eržen, R.</creator><creator>Lalek, N.</creator><creator>Bajrović, N.</creator><creator>Košnik, M.</creator><creator>Zidarn, M.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201510</creationdate><title>Immunological and clinical factors associated with adverse systemic reactions during the build-up phase of honeybee venom immunotherapy</title><author>Korošec, P. ; Žiberna, K. ; Šilar, M. ; Dežman, M. ; Čelesnik Smodiš, N. ; Rijavec, M. ; Kopač, P. ; Eržen, R. ; Lalek, N. ; Bajrović, N. ; Košnik, M. ; Zidarn, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3912-4634edd867a681541b9123b760691c8ca208af26af8a8eb241882300bfa703cd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>adverse systemic reactions</topic><topic>Aged</topic><topic>basophils</topic><topic>Basophils - immunology</topic><topic>Basophils - metabolism</topic><topic>Bee Venoms - administration & dosage</topic><topic>Bee Venoms - adverse effects</topic><topic>CD63</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>honeybee venom allergy</topic><topic>Humans</topic><topic>Hypersensitivity - blood</topic><topic>Hypersensitivity - immunology</topic><topic>IgE</topic><topic>immunotherapy</topic><topic>Immunotherapy - adverse effects</topic><topic>Male</topic><topic>Middle Aged</topic><topic>risk factors</topic><topic>Tetraspanin 30 - blood</topic><topic>Tetraspanin 30 - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Korošec, P.</creatorcontrib><creatorcontrib>Žiberna, K.</creatorcontrib><creatorcontrib>Šilar, M.</creatorcontrib><creatorcontrib>Dežman, M.</creatorcontrib><creatorcontrib>Čelesnik Smodiš, N.</creatorcontrib><creatorcontrib>Rijavec, M.</creatorcontrib><creatorcontrib>Kopač, P.</creatorcontrib><creatorcontrib>Eržen, R.</creatorcontrib><creatorcontrib>Lalek, N.</creatorcontrib><creatorcontrib>Bajrović, N.</creatorcontrib><creatorcontrib>Košnik, M.</creatorcontrib><creatorcontrib>Zidarn, M.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental allergy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Korošec, P.</au><au>Žiberna, K.</au><au>Šilar, M.</au><au>Dežman, M.</au><au>Čelesnik Smodiš, N.</au><au>Rijavec, M.</au><au>Kopač, P.</au><au>Eržen, R.</au><au>Lalek, N.</au><au>Bajrović, N.</au><au>Košnik, M.</au><au>Zidarn, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunological and clinical factors associated with adverse systemic reactions during the build-up phase of honeybee venom immunotherapy</atitle><jtitle>Clinical and experimental allergy</jtitle><addtitle>Clin Exp Allergy</addtitle><date>2015-10</date><risdate>2015</risdate><volume>45</volume><issue>10</issue><spage>1579</spage><epage>1589</epage><pages>1579-1589</pages><issn>0954-7894</issn><eissn>1365-2222</eissn><abstract>Summary
Background
Adverse systemic reactions (SRs) are more common in honeybee venom immunotherapy (VIT) than in wasp VIT. Factors that might be associated with SRs during the honeybee VIT are poorly understood.
Objective
Our aim was to evaluate risk factors for SRs during the build‐up phase of honeybee venom immunotherapy.
Methods
We included 93 patients who underwent ultra‐rush honeybee VIT. The adverse SRs and their severity was compared to various immunological (sIgE, tIgE, basophil CD63 response, baseline tryptase, and skin tests), patient‐specific (age, sex, cardiovascular conditions and medications, and other allergic diseases), and sting‐specific factors (anaphylaxis severity, time interval to onset of symptoms, and absence of cutaneous symptoms).
Results
Twenty‐three patients (24.7%) experienced mild SRs and 13 patients (14%) severe SRs. In five patients with severe SRs, the build‐up was stopped. High basophil allergen sensitivity, evaluated as dose–response curve metrics of EC15, EC50, CD‐sens, AUC, or the response to submaximal 0.01 μg/mL of venom concentration, was the most significant risk factor and only independent predictor of severe SRs and/or build‐up stop. Time interval of <5 min after sting to onset of symptoms and lower specific IgEs to rApi m1 was also associated with severe SRs. There was no difference in other immunological, patient‐specific, or sting‐specific factors, including the baseline tryptase. None of the studied factors was associated with mild SRs.
Conclusion and Clinical Relevance
High basophil allergen CD63 sensitivity phenotype was a major indicator of severe adverse SRs during the build‐up phase of honeybee VIT. Possibly role was also showed for short latency to filed sting reaction and low sIgE to rApi m1. Before honeybee VIT, measurement of basophil allergen sensitivity should be used to identify patients with a high risk for severe side‐effects.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>26046807</pmid><doi>10.1111/cea.12582</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0954-7894 |
| ispartof | Clinical and experimental allergy, 2015-10, Vol.45 (10), p.1579-1589 |
| issn | 0954-7894 1365-2222 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1713528117 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adolescent Adult adverse systemic reactions Aged basophils Basophils - immunology Basophils - metabolism Bee Venoms - administration & dosage Bee Venoms - adverse effects CD63 Dose-Response Relationship, Drug Female honeybee venom allergy Humans Hypersensitivity - blood Hypersensitivity - immunology IgE immunotherapy Immunotherapy - adverse effects Male Middle Aged risk factors Tetraspanin 30 - blood Tetraspanin 30 - immunology |
| title | Immunological and clinical factors associated with adverse systemic reactions during the build-up phase of honeybee venom immunotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T16%3A50%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunological%20and%20clinical%20factors%20associated%20with%20adverse%20systemic%20reactions%20during%20the%20build-up%20phase%20of%20honeybee%20venom%20immunotherapy&rft.jtitle=Clinical%20and%20experimental%20allergy&rft.au=Koro%C5%A1ec,%20P.&rft.date=2015-10&rft.volume=45&rft.issue=10&rft.spage=1579&rft.epage=1589&rft.pages=1579-1589&rft.issn=0954-7894&rft.eissn=1365-2222&rft_id=info:doi/10.1111/cea.12582&rft_dat=%3Cproquest_cross%3E1713528117%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1712393491&rft_id=info:pmid/26046807&rfr_iscdi=true |